Psilocybin-Research.comSearchable psilocybin and psilocin bibliometric database.Researcher index
Authors in the psilocybin and psilocin literature
Search researcher names, inspect publication history, find recurring topics, and create author watch alerts without collecting unverified contact lists.
Publication history
Assessing The Readiness of Psychiatrists in Louisiana to Incorporate Psilocybin into Clinical Practice-Lessons Learned from a State Underrepresented in Clinical Psychedelic Research.Psychedelic medicine (New Rochelle, N.Y.) · 2026-09-01Psilocybin as serotonergic therapy in epilepsy: Narrative review of potentials and limitationsBritish Journal of Clinical Pharmacology · 2026-07-21Blocking 5-HT2B receptors abolishes psilocybin's efficacy in the rat forced swim test.Journal of psychopharmacology (Oxford, England) · 2026-06-23Community engagement as a foundation for implementation research for group psilocybin assisted therapy in New MexicoFrontiers in Public Health · 2026-06-17Engineering artificial biosynthetic pathways for efficient microbial production of psilocybin and psilocinMetabolic Engineering · 2026-03-01Self-medication with psychedelics: a scoping review and narrative synthesis of review-level evidence.Exploratory research in clinical and social pharmacy · 2026-03-01Correction: Characteristics and mental health of psychedelic mushroom and multi-psychedelic users relative to non-psychedelic users in American adults, 2020-2021.Frontiers in psychiatry · 2026-01-01Real-World Psilocybin Therapy for Treatment-Resistant Depression: a Retrospective Observational StudyResearch Square · 2025-12-10Considerations and cautions for the integration of psilocybin into routine clinical care: a consensus statement from the US National Network of Depression Centers' Task Group on Psychedelics and Related Compounds.EClinicalMedicine · 2025-11-01Meditation, psychedelics, and brain connectivity: A randomized controlled resting-state fMRI study of N,N-dimethyltryptamine and harmine in a meditation retreatUniversität Zürich, ZORA · 2025-09-29An overview of psilocybin, LSD, MDMA, and ketamine in revitalizing psychedelic-assisted therapy: Insights, limitations and future directions.Progress in neuro-psychopharmacology & biological psychiatry · 2025-08-30Psilocybin-assisted therapy for treatment-resistant depression in the US: a model-based cost-effectiveness analysis.Translational psychiatry · 2025-08-29Evaluation of the Effect of a Single Dose of Psilocybin on Neural Correlates of Cognitive Control in Patients With Psychogenic Nonepileptic SeizuresClinicalTrials.gov · 2025-08-21Meditation, Psychedelics, and Brain Connectivity: A Randomised Controlled Resting-State fMRI Study of N,N-Dimethyltryptamine and Harmine in a Meditation RetreatmedRxiv · 2025-07-30595. Psilocybin-Assisted Therapy for Relapse Prevention in Alcohol Use Disorder: A RCTBiological Psychiatry · 2025-04-09The Emergence of Psilocybin in Psychiatry and Neuroscience.Pharmaceuticals (Basel, Switzerland) · 2025-04-09Psilocybin has a narrow therapeutic window as an antidepressant treatment.Progress in neuro-psychopharmacology & biological psychiatry · 2025-04-02Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trialUniversität Zürich, ZORA · 2025-04-01Psilocin, A Psychedelic Drug, Exerts Anticonvulsant Effects Against PTZ- and MES-Induced Seizures in Mice via 5-HT1A and CB1 Receptors: Involvement of Nitrergic, Opioidergic, and Kynurenine PathwaysPharmacology Research & Perspectives · 2025-04-01Alternative therapy for neurological and psychiatric disorders using psilocybinSão Paulo Medical Journal · 2025-01-01Characteristics and mental health of psychedelic mushroom and multi-psychedelic users relative to non-psychedelic users in American adults, 2020-2021.Frontiers in psychiatry · 2025-01-01Amid magic and menace: psychiatrists' attitudes to psilocybin therapy.Irish journal of psychological medicine · 2024-11-07An estimate of the number of people with clinical depression eligible for psilocybin-assisted therapy in the United StatesPsychedelics. · 2024-09-13Psilocybin in the Management of Substance Use Disorders: A Summary ofCurrent EvidenceCurrent Psychopharmacologye · 2024-07-04The influence of psilocybin on subconscious and conscious emotional learning.iScience · 2024-06-21Comparing Neural Correlates of Consciousness: From Psychedelics to Hypnosis and Meditation.Biological psychiatry. Cognitive neuroscience and neuroimaging · 2024-05-01Genetic regulation of L-tryptophan metabolism in Psilocybe mexicana supports psilocybin biosynthesis.Fungal biology and biotechnology · 2024-04-25Author Correction: Psilocybin enhances insightfulness in meditation: a perspective on the global topology of brain imaging during meditation.Scientific reports · 2024-04-23Psilocybin enhances insightfulness in meditation: a perspective on the global topology of brain imaging during meditation.Scientific reports · 2024-03-26Screening and confirmation of psilocin, mitragynine, phencyclidine, ketamine and ketamine metabolites by liquid chromatography-tandem mass spectrometryJournal of Analytical Toxicology · 2024-03-01A "Magic Mushroom" Multi-Product Sesquiterpene Synthase.Chembiochem: a European journal of chemical biology · 2023-11-02Psychedelics promote plasticity by directly binding to BDNF receptor TrkB.Nature neuroscience · 2023-06-01TMS-EEG and resting-state EEG applied to altered states of consciousness: oscillations, complexity, and phenomenology.iScience · 2023-05-19Are psychedelics the answer to chronic pain: A review of current literature.Pain practice: the official journal of World Institute of Pain · 2023-04-01Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial.EClinicalMedicine · 2023-02-01Corrigendum to 'Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial'.EClinicalMedicine · 2023-02-01Group psychedelic therapy: empirical estimates of cost-savings and improved access.Frontiers in psychiatry · 2023-01-01Psychedelics in the treatment of unipolar and bipolar depression.International journal of bipolar disorders · 2022-07-05The economics of psychedelic-assisted therapies: A research agenda.Frontiers in psychiatry · 2022-01-01Psilocybin Induces Time-Dependent Changes in Global Functional Connectivity.Biological psychiatry · 2020-07-15Molecular docking and binding interaction between psychedelic drugs and human serum albuminBiotechnologia · 2020-06-16Psilocybin exerts distinct effects on resting state networks associated with serotonin and dopamine in micebioRxiv · 2019-09-01Psilocybin modulates functional connectivity of the amygdala during emotional face discrimination.European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology · 2018-06-01LSD Increases Primary Process Thinking via Serotonin 2A Receptor Activation.Frontiers in pharmacology · 2017-01-01Psilocybin-induced decrease in amygdala-putamen coupling during an event-related face discrimination taskEuropean Neuropsychopharmacology · 2016-10-01Effects of serotonin 2A/1A receptor stimulation on social exclusion processing.Proceedings of the National Academy of Sciences of the United States of America · 2016-05-03The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity.NeuroImage. Clinical · 2016-01-01Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers.Biological psychiatry · 2015-10-15Psilocybin-induced spiritual experiences and insightfulness are associated with synchronization of neuronal oscillations.Psychopharmacology · 2015-10-01Spatiotemporal brain dynamics of emotional face processing modulations induced by the serotonin 1A/2A receptor agonist psilocybin.Cerebral cortex (New York, N.Y.: 1991) · 2014-12-01P.1.g.005 Serotonergic modulation of emotion processing by the mixed 5-HT1A/2A receptor agonist psilocybin reduces amygdala activation to negative stimuli - a pharmacological fMRI studyEuropean Neuropsychopharmacology · 2014-09-25The NMDA antagonist ketamine and the 5-HT agonist psilocybin produce dissociable effects on structural encoding of emotional face expressions.Psychopharmacology · 2013-01-01Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors.Biological psychiatry · 2012-12-01Mismatch negativity encoding of prediction errors predicts S-ketamine-induced cognitive impairments.Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology · 2012-03-01Enhancement of Indole Alkaloids Produced by Psilocybe cubensis (Earle) Singer (Agaricomycetideae) in Controlled Harvesting Light ConditionsInternational journal of medicinal mushrooms · 2009-01-01[DNA and chemical analyses of commercial fly agaric-related products].Shokuhin eiseigaku zasshi. Journal of the Food Hygienic Society of Japan · 2005-04-01Preparation of Monoclonal Antibodies Reactive to a Hallucinogenic Drug, PsilocinJournal of Health Science · 2004-01-01[Discrimination of psychoactive fungi (commonly called "magic mushrooms") based on the DNA sequence of the internal transcribed spacer region].Shokuhin eiseigaku zasshi. Journal of the Food Hygienic Society of Japan · 2003-02-01The pharmacology of psilocybin.Addiction biology · 2002-10-01Effects of chlorpromazine and psilocin on pregnancy of c57bl/10 mice and their offspring at birth. Abstr.The Mouseion at the JAXlibrary (Jackson Laboratory) · 1967-01-01The effects of psilocybin and lycergic acid on the extinction of avoidance behavior in rats.The Mouseion at the JAXlibrary (Jackson Laboratory) · 1961-01-01